Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.

Phase 1

Completed

• Conditions: Neoplasms

• Registration Number: NCT00091585
• Lead Sponsor: Sunesis Pharmaceuticals

Brief Summary

The purpose of this study is to determine whether SNS-595 given intravenously once every 3 weeks is safe.

Detailed Description

Other objectives of this study include measuring pharmacokinetics (how long the drug can be measured in the blood) and determining the dose and dose schedule for the next phase of studies with SNS-595.

Study Timeline

• Study Start: 2004-06
• Study First Submitted: 2004-09-10
• Study First Submitted QC: 2004-09-13
• Study First Posted: 2004-09-14
• Study Completion: 2006-11
• Status Verified: 2007-05
• Last Update Submitted: 2007-05-09
• Last Update Posted: 2007-05-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Must give written informed consent
• 18 years of age
• Advanced solid malignant tumors
• Tumor can be measured and evaluated
• Blood tests are within standard limits
• Normal blood coagulation
• ECOG Performance Status equal to 0 or 1

Exclusion Criteria

• Pregnant or breastfeeding.
• Women of childbearing potential unwilling to use an approved, effective means of contraception according to the institution's standards.
• Heart attack, stroke/TIA or other blood clotting event (deep vein thrombosis or pulmonary embolus) within 6 months before the screen visit.
• Requires kidney dialysis (hemodialysis or peritoneal).
• Known bleeding disorder (ie, hemophilia, von Willebrand Disease, coagulopathy, etc.).
• Received an investigational agent or prior chemotherapy or immunotherapy within 28 days before first dose of SNS-595
• Receiving therapeutic anticoagulation therapy (coumadin, heparin, etc.).
• Currently receiving corticosteroids (inhaled steroids for breathing diseases are allowed) or seizure medications.
• Any medical, psychological, or social condition that, in the opinion of the Principal Investigator, would contraindicate the patient's participation in the clinical trial due to safety and or compliance with study procedures.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (3)

Arizona Cancer Center; 🇺🇸 Tucson, Arizona, United States

Stanford University Medical Center; 🇺🇸 Stanford, California, United States

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States